Login to Your Account


First antibody directly targeting Ras oncogenes is now developed

By John Fox
Staff Writer

Wednesday, May 17, 2017

The first therapeutic monoclonal antibody (MAb) that selectively targets activated intracellular cytosolic Ras mutant proteins, which are inaccessible to current antibodies, has been developed and assessed preclinically in a new South Korean study.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription